Drug General Information |
Drug ID |
D04KWO
|
Former ID |
DIB003451
|
Drug Name |
MEDl-551
|
Drug Type |
Antibody
|
Indication |
Scleroderma [ICD9: 701.0710.1; ICD10:L94.0-L94.1, M34]
|
Phase 1 |
[1]
|
Company |
Astrazeneca; medimmune
|
Target and Pathway |
Target(s) |
B-lymphocyte antigen CD19 |
Target Info |
|
[1]
|
KEGG Pathway
|
PI3K-Akt signaling pathway
|
Hematopoietic cell lineage
|
B cell receptor signaling pathway
|
Epstein-Barr virus infection
|
Primary immunodeficiency
|
NetPath Pathway
|
IL-7 Signaling Pathway
|
PANTHER Pathway
|
B cell activation
|
Pathway Interaction Database
|
BCR signaling pathway
|
Reactome
|
PIP3 activates AKT signaling
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
Constitutive Signaling by Aberrant PI3K in Cancer
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
WikiPathways
|
Human Complement System
|
Signaling by the B Cell Receptor (BCR)
|
PIP3 activates AKT signaling
|
B Cell Receptor Signaling Pathway
|
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
References |
REF 1 | CD19 as an attractive target for antibody-based therapy. MAbs. 2012 Sep-Oct;4(5):571-7. |